Physician profile
William G Pujadas
NPI 1083618854
$2,914.78
in general payments reported to CMS, 2019-2025
23 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $84.97 · 2021: $224 · 2022: $430 · 2023: $1,116 · 2024: $144 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230 · Travel and Lodging: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.76 |
| Travel and Lodging | $248.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,175.97 | 2019-2025 | Comprehensive Shoulder System, Juggerknotless Soft Anchor |
| Sanara Medtech INC. | $410.82 | 2021-2023 | Celleraterx |
| Heron Therapeutics, INC. | $176.90 | 2022 | |
| Davol INC. | $143.24 | 2023-2025 | |
| Trice Medical, INC. | $129.84 | 2019 | |
| Smith+Nephew, INC. | $89.61 | 2022-2023 | Coblation |
| Nextstep Arthropedix, LLC | $86.50 | 2019 | |
| Innovation Technologies INC | $84.78 | 2023-2025 | Irrisept |
| Depuy Synthes Sales INC. | $82.10 | 2019-2022 | |
| Ermi LLC | $69.65 | 2019 | |
| Ethicon US, LLC | $61.53 | 2022-2023 | Surgicel Nu-Knit, Surgiflo Hemostatic Matrix, Vistaseal |
| Bone Support INC. | $56.20 | 2021 | |
| Bioventus LLC | $54.98 | 2024 | Durolane |
| Pacira Therapeutics, INC. | $51.89 | 2019-2020 | |
| Team 1, LLC | $44.99 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $42.39 | 2019-2020 | |
| Convatec INC. | $32.82 | 2023 | |
| Dynasplint Systems INC. | $31.07 | 2024-2025 | Dynasplint |
| Pacira Pharmaceuticals Incorporated | $24.15 | 2023 | Zilretta, Iovera, Exparel |
| Vertex Pharmaceuticals Incorporated | $21.44 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.60 | 2023 | Seglentis |
| Ferring Pharmaceuticals INC. | $14.53 | 2019 | |
| Vericel Corporation | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pujadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.